Alcoholism-treatment medication acamprosate may help abstinent alcoholics sleep better

August 27, 2006

Alcoholics generally don't sleep well. Nor does abstinence improve the situation much. In fact, sleep difficulties during alcohol abstinence may be responsible for a relapse to alcoholism as individuals attempt to self medicate their sleeping problems. New findings show that an alcoholism-treatment drug called acamprosate, widely used in Europe, can alleviate post-withdrawal sleep disturbances by influencing glutamatergic transmission.

Results are published in the September issue of Alcoholism: Clinical & Experimental Research.

"During chronic and excessive use of alcohol, short periods of deep sleep become interrupted by brief periods of restlessness," said Luc Staner, director of the Sleep Laboratory of the Centre Hospitalier de Rouffach. "This may also be accompanied by sleep terrors, sleepwalking and exacerbation of loud snoring or sleep apnea. During the day, alcohol intake can exacerbate sleepiness, which disrupts performance and contributes to accidents even when an individual is not significantly intoxicated." Staner is also a researcher at FORENAP, an organization that specializes in early drug development and research in neuroscience, located in Rouffach, France.

Sleep dysfunction does not necessarily improve with abstinence from alcohol, added Staner, who is also the corresponding author for the study. "Sleep is initially characterized by occasional nights of very little sleep and nightmares, followed by either progressive improvement or, very often, long-lasting sleep difficulties," he said. "If the latter, consequences may include decreased attention, vigilance, energy and concentration; increase in fatigue and malaise, irritability, etc. These often protracted symptoms lead some patients to resume drinking in an attempt to self-medicate their sleep problems. Probably for this reason, persistent post-withdrawal sleep complaints have been shown to predict relapse to alcoholism."

"These sleep problems among abstinent alcoholics construe a critical issue, as they can remain for up to three years," added Timothy A. Roehrs, director of research at the Sleep Disorders and Research Center at Henry Ford Hospital, as well as professor of psychiatry and neurobehavioral sciences at Wayne State University School of Medicine in Detroit. "This would be the first study of its kind to show positive effects of acamprosate on sleep disorders."

The seemingly greater popularity of acamprosate in Europe, noted Staner, is probably due to the fact that the drug was approved by many European countries in the early 1990s, long before naltrexone (another alcoholism-treatment medication). "The drug is very safe to use and there is no cross-tolerance with alcohol," he said.

Study participants (n=24 males) were recruited through physician referral or a local hospital outpatient department; all were confirmed as alcohol dependent according to the Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition. Beginning eight days before alcohol withdrawal, in order to reach steady levels in patient plasma, and continuing for 15 days following withdrawal, researchers administered either acamprosate (two tablets of 333 mg) or a placebo. Polysomnographic assessments were recorded during acute withdrawal (the first two nights following withdrawal), as well as during post-withdrawal abstinence (the last two nights of the study period).

"Compared to the placebo," said Staner, "results indicate that acamprosate objectively improves sleep disturbances of alcohol-dependent patients who are trying to stop alcohol intake. This effect was observed during the first withdrawal night and was maintained after two weeks of treatment. On a more mechanistic level, these results appear to implicate glutamate in both sleep disturbances and withdrawal symptoms, and acamprosate appears to be able to decrease the physiological effects of glutamate in the brain."

Given that this was a very short-term study, Roehrs said he is hopeful that future research will address what the long-term impact of acamprosate may be. He would also like to learn more about helping those individuals for whom acamprosate does not alleviate sleep problems.
Alcoholism: Clinical & Experimental Research (ACER) is the official journal of the Research Society on Alcoholism and the International Society for Biomedical Research on Alcoholism. Co-authors of the ACER paper, "The Effects of Acamprosate on Sleep During Alcohol Withdrawal: A Double-Blind Placebo Controlled Polysomnographic Study in Alcohol-Dependent Subjects," were: Peter Boeijinga, IsabelleGendre, Muriel Muzet and Rémy Luthringer of FORENAP at Centre Hospitalier de Rouffach, France; Thierry Danel of the Unité de psychopathologie et alcoologie clinique de l'anxiété of Lille, France; and Frédéric Landron of MERCK Santé of Lyon, France. The study was funded by Merck Santé.

Alcoholism: Clinical & Experimental Research

Related Alcohol Articles from Brightsurf:

Alcohol use changed right after COVID-19 lockdown
One in four adults reported a change in alcohol use almost immediately after stay-at-home orders were issued: 14% reported drinking more alcohol and reported higher levels of stress and anxiety than those who did not drink and those whose use stayed the same.

Changes in hospitalizations for alcohol use disorder in US
Changes over nearly two decades in the rate of hospitalizations and in-hospital deaths from alcohol use disorder in the US were examined in this study.

Associations of alcohol consumption, alcohol-induced passing out with risk of dementia
The risk of future dementia associated with overall alcohol consumption and alcohol-induced loss of consciousness in a population of current drinkers was examined in this observational study with more than 131,000 adults.

New alcohol genes uncovered
Do you have what is known as problematic alcohol use?

Does estrogen influence alcohol use disorder?
A new study from researchers at the University of Illinois at Chicago shows that high estrogen levels may make alcohol more rewarding to female mice.

Sobering new data on drinking and driving: 15% of US alcohol-related motor vehicle fatalities involve alcohol under the legal limit
A new study in the American Journal of Preventive Medicine, published by Elsevier, found that motor vehicle crashes involving drivers with blood alcohol concentrations (BACs) below the legal limit of 0.08 percent accounted for 15% of alcohol-involved crash deaths in the United States.

Alcohol-induced deaths in US
National vital statistics data from 2000 to 2016 were used to examine how rates of alcohol-induced deaths (defined as those deaths due to alcohol consumption that could be avoided if alcohol weren't involved) have changed in the US and to compare the results by demographic groups including sex, race/ethnicity, age, socioeconomic status and geographic location.

Cuts in alcohol duty linked to 2000 more alcohol-related deaths in England
Government cuts to alcohol taxes have had dramatic consequences for public health, including nearly 2000 more alcohol-related deaths in England since 2012, according to new research from the University of Sheffield's School of Health and Related Research (ScHARR).

Integrated stepped alcohol treatment for people in HIV care improves both HIV & alcohol outcomes
Increasing the intensity of treatment for alcohol use disorder (AUD) over time improves alcohol-related outcomes among people with HIV, according to new clinical research supported by the National Institutes of Health.

The Lancet:Targets to reduce harmful alcohol use are likely to be missed as global alcohol intake increases
Increasing rates of alcohol use suggest that the world is not on track to achieve targets against harmful alcohol use, according to a study of 189 countries' alcohol intake between 1990-2017 and estimated intake up to 2030, published in The Lancet.

Read More: Alcohol News and Alcohol Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to